United States Liquid Biopsy Market to Experience 6-8% CAGR Growth by 2028

United States Liquid Biopsy Market to Experience 6-8% CAGR Growth by 2028: Rising Cancer Rates and Growing Demand for Minimally Invasive Procedures
By: Makreo Research And Consulting
LOS ANGELES - Jan. 7, 2023 - PRLog -- The market is expanding as a result of the rising incidence of cancer and the preference for minimally invasive medical procedures.

Changing Treatment Methods:
The way cancer is treated has fundamentally changed as a result of liquid biopsy, a rapid, painless process that provides a superior alternative to invasive surgical biopsies. It helps the medical professionals discover a wealth of knowledge about the tumour through a little sample.

The non-invasiveness of liquid biopsy is the main element influencing its great demand among medical professionals. It is less invasive, more convenient, and quicker for patients than other treatments because just 5 milliliters of blood are required.

Industry Updates
  • NeXT Liquid Biopsy, a high-performance, exomescale tumor-profiling device that uses blood samples from patients with advanced-stage solid tumour malignancy, was introduced by Personalis Inc. in 2020.
  • California accounts for the major market share due to increasing number of cancer patients and increasing adoption of novel liquid biopsy tests across the cities.
  • A merger with HH&L Acquisition Co. will result in DiaCarta becoming a public company with a pre-money equity value of USD 460 million on a fully diluted basis. The transaction is expected to close in the first quarter of 2023.
  • Mesa Biotech was acquired by Thermo Fisher, which develops and commercializes PCR-based rapid point-of-care testing platforms for diagnosing diseases such as SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus.

It is anticipated that circular tumour cells will remain dominant even in the coming years. The escalating cancer rate and the development of ctDNA-based liquid biopsy analysis, which can assess prognosis and tumour progression, are driving the market demand for Circulating tumour DNA (ctDNA).

A detailed study has been conducted by Makreo Research titled "United States Liquid Biopsy Market Revenue and Forecast to 2028" that assess the present adoption rate of the newly introduced biopsy technique in the US market and also highlights future expected growth.

Report covers below areas:
  • Biomarkers Type (Cell-Free DNA (cfDNA) and Circulating Tumor DNA (ctDNA)
  • Product (Kits & Consumables, Instruments and Services)
  • Therapeutic Application (Oncology and Non-Cancer Biopsy)
  • Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer)
  • Prevalence in Cities

To know more about publication checkout our report:-
United States Liquid Biopsy Market Revenue and Forecast to 2028 (https://www.makreo.com/report/united-states-liquid-biopsy...)

Contact us on-
Makreo Research and Consulting
Send us query at info@makreo.com

Related Press Release:-

Media Contact
Ankit Suri
Posted By:***@makreo.com Email Verified
Tags:Liquid biopsy report 2028
Location:Los Angeles - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jan 27, 2023
Makreo Research News
Most Viewed
Daily News

Like PRLog?
Click to Share